GlassScriptPhysician profile
Elizabeth Rodriguez
NPI 1134823446
$5,260.40
in general payments reported to CMS, 2019-2025
28 companies · $3,339 in 2025
The $3,339 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $584 · 2024: $1,338 · 2025: $3,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526 · Consulting Fee: $1,650 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.41 |
| Consulting Fee | $1,650.00 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,411.94 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $309.43 | 2023-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $176.27 | 2024-2025 | Xcopri |
| Ucb, INC. | $161.97 | 2023-2025 | Briviact, Nayzilam |
| Pfizer INC. | $122.87 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $114.78 | 2024-2025 | Austedo Xr, Austedo Xr |
| Janssen Biotech, INC. | $83.99 | 2025 | |
| Lundbeck LLC | $76.16 | 2024-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $73.47 | 2023-2025 | Rytary, Crexont |
| Avadel Cns Pharmaceuticals, LLC | $72.32 | 2025 | Lumryz |
| Azurity Pharmaceuticals, INC. | $60.42 | 2024 | Horizant |
| Lilly USA, LLC | $58.76 | 2025 | Kisunla, Amyvid |
| Neurelis, INC. | $50.33 | 2025 | Valtoco |
| Eisai INC. | $46.87 | 2024-2025 | |
| Impel Pharmaceuticals LLC | $45.47 | 2024 | Trudhesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $43.90 | 2023-2024 | Nuedexta, Rexulti |
| Scilex Pharmaceuticals INC. | $39.85 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $39.57 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $34.62 | 2025 | Ultomiris |
| Kyowa Kirin, INC. | $34.61 | 2024 | Nourianz |
| Argenx US, INC. | $32.76 | 2025 | Vyvgart Hytrulo |
| Csl Behring | $32.09 | 2023 | Hizentra |
| Jazz Pharmaceuticals INC. | $30.80 | 2023-2025 | Xywav |
| Takeda Pharmaceuticals U.S.A., INC. | $25.17 | 2025 | Hyqvia |
| Axsome Therapeutics, INC. | $24.71 | 2023 | Auvelity |
| Tanabe Pharma America, INC. | $22.49 | 2025 | Radicava |
| Astrazeneca Pharmaceuticals LP | $19.60 | 2025 | Wainua |
| Avion Pharmaceuticals | $15.18 | 2023 | Dhivy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.